RetinalGenix Technologies

RTGN · OTC

$3.99+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

Key indicators

RTGN profitability and balance sheet ratios

Return on assets -126.5% in Jun 2026, down 38.0 points on a year earlier.

Return on assets by quarter
PeriodReturn on assets
Sep 2024-70.5%
Dec 2024-71.6%
Mar 2025-54.5%
Jun 2025-88.6%
Sep 2025-252.9%
Dec 2025-200.9%
Mar 2026-230.3%
Jun 2026-126.5%

Where the money went

Q1 FY15, from revenue to net income

RetinalGenix Technologies brought in $0.1M of revenue in Q1 FY15. It made a net loss of $1.8M.

Revenue
$0.1M
Costs, expenses and taxes
$1.9M
Net income
−$1.8M
Net margin
-1717.1%

Income statement

Revenue and profit by reporting period

Revenue
Net income
RTGN income statement, quarterly
Line itemQ3 FY14Q4 FY14Q1 FY15
Revenue$0.0M$0.3M$0.1M
Gross profit$0.0M$0.3M$0.1M
Operating income−$2.6M−$1.6M−$2.7M
Net income−$11.1M$15.2M−$1.8M
Diluted EPS-$11,920.00$16,252.00-$1,910.00

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
RTGN balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$0.0M$0.0M$0.0M
Total liabilities$2.3M$2.6M$2.7M
Shareholder equity−$2.3M−$2.6M−$2.6M
Cash and short-term investments$0.0M$0.0M$0.0M
Total debt$0.0M$0.0M$0.0M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
RTGN cash flow, quarterly
Line itemQ3 FY14Q4 FY14Q1 FY15
Operating cash flow−$2.6M−$1.8M−$2.2M
Investing cash flow−$0.0M−$0.1M−$0.0M
Financing cash flow$1.8M$1.6M$4.5M
Capital expenditure−$0.0M−$0.1M−$0.0M
Free cash flow−$2.6M−$1.9M−$2.2M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.